AzTrials
AzTrials

Seasonal Allergic RhinitisPhase 3NCT05540717

Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen

A Phase 3 study testing PQ Grass in people with Seasonal Allergic Rhinitis and Rhinoconjunctivitis, run by Allergy Therapeutics at 102 sites in 6 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The PQGrass306 (G306) clinical trial is the pivotal Phase III efficacy clinical trial of PQ Grass. The aim of the G306 pivotal clinical trial is to confirm the efficacy and safety of the optimal effective dose of PQ Grass 27600 SU. Read more about this study

Who is it for?
Ages 18 to 65 years
What is being tested?
PQ Grass
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
555 participants
Where
102 sitesin 6 countries
Study dates
11 Oct 2022to 1 Nov 2023
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the ICF (informed consent form) and in this clinical trial protocol and to attend required clinical trial visits.
  • Subject who has a signed and dated ICF.
  • Subject must be 18 to 65 years of age inclusive, at the time of signing the ICF.
  • Male or female.
  • Female subjects who are not of childbearing potential (defined as at least 12 months natural spontaneous amenorrhoea, or at least 6 weeks following surgical menopause/permanent sterilisation [hysterectomy, bilateral oophorectomy and bilateral salpingectomy]) or females of childbearing potential who agree to comply with the contraceptive requirements of the clinical trial protocol.
  • Good general health, as determined by the Investigator, based on a medical evaluation, including medical history, physical examination, mental status assessment and laboratory tests. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator agrees that the finding is unlikely to introduce additional risk factors and will not interfere with the clinical trial procedures.
Show all 12Show fewer
  • Positive history of moderate to severe symptoms of SAR/rhinoconjunctivitis ascribed to grass (Pooideae) pollen exposure of at least 2 seasons duration, despite having received allergy pharmacotherapy (e.g., antihistamines, nasal corticosteroids, leukotriene modifiers, etc.) during the last 2 consecutive grass pollen seasons prior to the clinical trial, confirmed by subject records.
  • Please note: Subjects with asthma may be included, but the asthma must be well controlled (according to current Global Initiative for Asthma [GINA] guidelines [GINA 2022]).
  • A positive SPT (skin prick test) to histamine (wheals [longest diameter] ≥3 mm) and a negative SPT to the negative control (wheal diameter = 0 mm) at screening.
  • A positive SPT for grass pollen (wheals [longest diameter] ≥3 mm).
  • Grass specific IgE (immunoglobulin E) class ≥2 as documented by an ImmunoCAP test at screening.
  • Forced expiratory volume in one second (FEV1) ≥70% of predicted, with a FEV1/forced vital capacity (FVC) ratio >75% and PEFR (peak expiratory flow rate) ≥70% of predicted at screening.

Who cannot join

  • Pregnant or lactating subject.
  • Presence of any medical history of moderate to severe allergy symptoms (verified by a positive SPT at screening or positive specific IgE [≥2] at screening) to any other seasonal allergen (other than grass) or perennial allergens.
  • Exception: Period 1, Period 2 and Period 3 of the entire clinical trial will be conducted outside of the pollen season(s) of concern or perennial allergies are irrelevant due to avoidance measures (e.g., cats and dog allergy). Subjects with mild allergy symptoms (only) to any other allergen apart from grass may be included at the discretion of the Investigator. In countries in Europe where Bermuda grass is present, any medical history of moderate to severe allergy symptoms to Bermuda grass (verified by a positive SPT or positive specific IgE [Class ≥2]), will also represent a reason for exclusion as it will not be possible to conduct Period 1, Period 2 and Period 3 of the entire clinical trial outside of Bermuda grass pollen season. Albeit Bermuda grass being commonly defined as a grass, it belongs to the Poaceae family, while the sentence (other than grass) in Exclusion criterion #2 refers to grass of Pooideae subfamily (as defined in Inclusion criterion #7).
  • Subjects at US clinical trial sites in regions where southern grasses (Bahia grass, Bermuda grass or Johnson grass) are the dominant grasses and the main cause of grass allergy symptoms with a positive SPT to any of the 3 grasses (irrespective of the severity of symptoms).
  • Moderate to severe symptoms during the 3 years prior to Visit 1 to any other seasonal or perennial allergen not tested in the SPT done at screening that cannot be avoided during the Period 1 to Period 3 of the clinical trial and the symptoms of which may interfere with administration of treatment and/or impact the data collected.
  • Presence of any medical condition that may reduce the ability to survive a serious allergic reaction.
Show all 55Show fewer
  • Presence of active systemic autoimmune disorder, systemic autoimmune disorders in remission or active organ specific autoimmune disorder.
  • Presence of active malignant neoplasia, severe cardiovascular disease (e.g., coronary artery disease, cardiac insufficiency, etc.), pulmonary insufficiency, severe psychiatric disorders or primary and secondary immunodeficiencies.
  • History of any other immunological disorder or other diseases (including, but not limited cardiovascular [including uncontrolled or inadequately controlled hypertension], gastro-intestinal, hepatic, renal, haematological, neurological, endocrine or pulmonary disease) that in the opinion of the Investigator may pose a safety risk or compromise the interpretation of efficacy of the clinical trial treatment.
  • Presence of severe or poorly controlled or uncontrolled asthma as defined by at least 1 of the following criteria:
  • Severe asthma (as per the current GINA guidelines [GINA, 2022]).
  • Uncontrolled or poorly controlled asthma as per the current GINA guidelines (GINA, 2022).
  • Asthma that requires more than a daily dose above 800 μg of inhaled budesonide (or clinically comparable inhaled corticosteroid) as per the current GINA guidelines (GINA, 2022).
  • History of 2 or more systemic corticosteroid courses within 6 months of screening or Visit 2 or 1 course of systemic corticosteroids within 3 months of screening or Visit 2 to treat asthma.
  • Prior intubation/mechanical ventilation for asthma.
  • Emergency room visit or hospitalisation for asthma in the 12 months prior to screening or Visit 2.
  • Any history of a life-threatening asthma attack.
  • FEV1 <70% of predicted or FEV1/FVC ≤75% or PEFR <70% of predicted with or without controller medications at screening or Visit 2.
  • Presence non-atopic rhinitis and/or rhino-sinusitis (with or without polyps).
  • Presence of nasal polyps and/or chronic sinusitis.
  • Presence of any acute or chronic ocular disorder, other than allergic conjunctivitis.
  • Eye surgery within the past 6 months.
  • Presence of any skin conditions (e.g., skin abnormalities, tattoos etc.), which might interfere with the interpretation of the SPT results.
  • Clinical history of Type I diabetes or poorly controlled Type II diabetes.
  • Moderate to severe upper or lower respiratory infections requiring medication within 14 days before screening (Visit 1) or Visit 2.
  • Presence of acute or chronic infection, fever or inflammation at screening or Visit 2.
  • Clinical history of severe systemic reaction or serious systemic reaction in response to AIT (allergen immunotherapy) in the past.
  • Clinical history of severe or life-threatening anaphylactic reactions to foods, insect venom, exercise, drugs or idiopathic anaphylaxis.
  • Clinical history of allergy, hypersensitivity or intolerance to the excipients of the investigational drug/placebo.
  • Clinical history of allergy, hypersensitivity or intolerance to the relief medications (for relief of allergy symptoms during Period 3) provided for use in this clinical trial.
  • Clinical history of hereditary angioedema.
  • Unable to receive epinephrine therapy (i.e., use of epinephrine is contraindicated such as in subjects with hyperthyroidism, uncontrolled hypertension, cardiac arrhythmias, closed angle glaucoma or subjects taking other sympathomimetics).
  • Tyrosine metabolism disorders, especially tyrosinemia and alkaptonuria.
  • Clinical history of drug or alcohol abuse, which, in the Investigator's opinion, could interfere with the subject's ability to participate in the clinical trial.
  • Subjects who have suspicion or symptoms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (as assessed by the Investigator) or who have had unprotected contact with a confirmed case of COVID-19 (coronavirus disease 2019) in the 2 weeks prior to screening or Visit 2 (based on the Investigator's discretion).
  • Subjects who were hospitalised for COVID-19 within 6 months prior to screening or Visit 2.
  • Any history of AIT for grass pollen allergy in the past or history of AIT for any other type of allergy (excluding food allergy) in the past 5 years.
  • Inability to adhere to the washout periods listed in the protocol, with respect to screening and to refrain from using the medications indicated until after Visit 11.
  • Treatment with a preparation containing MPL (monophosphoryl lipid-A) (e.g., Cervarix, Shingrix, Fendrix) within 2 years prior to Visit 1 and until after completion of Visit 11 (with the exception of the investigational drug).
  • Previous history of epinephrine auto-injector use.
  • β-blocker medication (local or systemic, including eye drops) for any indication.
  • Monoamine oxidase inhibitors and tricyclic antidepressants. Please note: Tricyclic antidepressants should be avoided at least 2 weeks prior to screening.
  • Any previous therapy (within the previous 5 years) or current therapy with anti IgE (e.g., omalizumab [Xolair]) or anti-interleukins (e.g., mepolizumab).
  • Current or past therapy (within the previous 5 years) with any other immunomodulatory biologics.
  • Unable to refrain from any vaccination (including influenza vaccine and COVID-19 vaccine) during the clinical trial (unless administered >30 days prior to randomisation).
  • Please note: Emergency vaccinations (e.g., tetanus due to injury) can be administered at any time. Booster vaccinations (only) for COVID-19 can be administered during the clinical trial apart from during the treatment period. There should be at least 14 days interval from the last administration of the investigational drug/placebo prior to administration of a COVID-19 booster injection.
  • Participation in a clinical research trial with any investigational drug within 4 weeks of Visit 1 or concomitantly with this clinical trial.
  • Please note: The period of exclusion begins at the time of the last visit of the prior clinical research trial. Subjects consented and screened, but not dosed in the prior clinical research trial are not excluded.
  • Personal, financial or other dependent relationship (e.g., employee or immediate relative) with the clinical trial site, Sponsor, Sponsor's representative, or another individual who has access to the clinical trial protocol.
  • Vulnerable subjects or those in judicial or governmental detention, detainment or imprisonment in a public institution.
  • Subjects likely to have prolonged periods of absence (e.g., business or personal travel) during the GPS defined as:
  • Absence of a total of 22 days or more in similar geographical regions (as determined by the Investigator), with no single trip in a similar geographical region exceeding 14 days.
  • Absence of a total of 15 days or more in non-similar geographic regions (as determined by the Investigator), with no single trip in a non-similar geographical region exceeding 7 days.
  • Have changed residence to a different geographical region(s) since the last GPS.
  • Exception: The old and new residences are in the same or similar geographical region as determined by the Investigator.

Trial locations and contacts

102 sites in 6 countries.

102 sites in 6 countries

United States33 sites

  • Northern Light Allergy and Immunology

    Bangor, Maine, 04401

  • Paul A. Shapero M.D.

    Bangor, Maine, 04401

  • Nebraska Medical Research Institute, The Asthma & Allergy Center

    Bellevue, Nebraska, 68123

  • Bellingham Asthma Allergy and Immunology Clinic

    Bellingham, Washington, 98225

  • Allergy & Asthma Specialists

    Blue Bell, Pennsylvania, 19422

  • IMMUNOe Research Centers

    Centennial, Colorado, 80112

  • Allergy Asthma and Immunology Research Institute

    Charlotte, North Carolina, 28204

  • Cincinnati Allergy and Asthma Center

    Cincinnati, Ohio, 45209

  • Bernstein Clinical Research Center, LLC

    Cincinnati, Ohio, 45236

  • Clinical Research of The Ozarks Inc - Warrensburg

    Columbia, Missouri, 65203

  • Optimed Research Ltd

    Columbus, Ohio, 43235

  • Velocity Clinical Research Denver

    Denver, Colorado, 80209

  • Lysosomal Rare Disorders Research & Treatment Center

    Fairfax, Virginia, 22030-7404

  • Velocity Clinical Research, Inc

    Grants Pass, Oregon, 97527

  • Allergy, Asthma & Sinus Center, S.C.

    Greenfield, Wisconsin, 53228

  • Parikh Institute for Research LLC

    Highland Park, New Jersey, 08904

  • Allergy Partners of Central Kentucky

    Lexington, Kentucky, 40503

  • Allergy and Asthma Associates of Bluegrass

    Lexington, Kentucky, 40509

  • Family Allergy Asthma Research Institute

    Louisville, Kentucky, 40202

  • University of Wisconsin Clinical Science Center

    Madison, Wisconsin, 53792

  • Velocity Clinical Research - Medford - ERN - PPDS

    Medford, Oregon, 97504

  • Montana Medical Research

    Missoula, Montana, 59808

  • Allergy Associate of Utah

    Murray, Utah, 84107

  • Eastern Virginia Medical School

    Norfolk, Virginia, 23507

  • Atlantic Research Center LLC

    Ocean City, New Jersey, 07712

  • Oklahoma Institute of Allergy and Asthma Clinical Research, LLC - CRN - PPDS

    Oklahoma City, Oklahoma, 73131

  • Allergy & Asthma Specialists PSC

    Owensboro, Kentucky, 42301

  • Allergy and Clinical Immunology Associates

    Pittsburgh, Pennsylvania, 15241

  • Northwest Research Center

    Portland, Oregon, 97202

  • Weiss Medical

    Riverdale, New Jersey, 07457

  • Toledo Institute of Clinical Research Inc

    Toledo, Ohio, 43617

  • Chesapeake Clinical Research Inc

    White Marsh, Maryland, 21162

  • Respiratory Medicine Research Institute of Michigan

    Ypsilanti, Michigan, 48197

Other trials in United States

Germany29 sites

  • CIMS Studienzentrum Bamberg, GmbH

    Bamberg, 96049

  • Charité - Universitaetsmedizin Berlin Klinik fuer Dermatologie, Venerologie und Allergologie/ Abteilung Allergologie und Immunologie

    Berlin, 10117

  • Praxis Dr. Petra El-Naib

    Chemnitz, 09130

  • HNO-Praxis Dr. Udo Schaefer

    Dresden, 01067

  • Klinische Forschung Dresden GmbH

    Dresden, 01069

  • Praxis fuer HNO und Allergologie

    Dresden, 01139

  • Universitaetsklinikum Carl Gustav Carus an der TU Dresden

    Dresden, 01307

  • HNO-Praxis Dr. Uta Thieme

    Duisburg, 47051

  • RKM740 Hals-Nasen-Ohrenheilkunde

    Düsseldorf, 40549

  • Gemeinschaftspraxis Ruhr

    Essen, 45277

  • Medizentrum Essen Borbeck

    Essen, 45355

  • Medaimun GmbH

    Frankfurt am Main, 60596

  • medicoKIT GmbH

    Goch, 47574

  • Klinische Forschung Hamburg GmbH

    Hamburg, 20253

  • Hamburger Institut für Therapieforschung GmbH

    Hamburg, 20354

  • Velocity Clinical Research Hamburg

    Hamburg, 22143

  • Praxis Dres. med. Florian Heimlich und Angelika Witzel-Heimlich

    Heidelberg, 69126

  • HNO-Praxis Landsberg

    Landsberg, 06188

  • Praxis fuer Pneumologie und Allergologie

    Leipzig, 04299

  • Sektion Rhinologie/Allergologie Klinik fuer HNO-Heilkunde, UKGM - Marburg

    Marburg, 35043

  • Beldio Research GmbH

    Memmingen, 87700

  • Facharztpraxis Dr. med. Jan-Christof Bohn

    Mittweida, 09648

  • Ballenberger, Freytag, Wenisch Institut fuer klinische Forschung GmbH

    Neu-Isenburg, 63263

  • Studienzentrum Maerkisch-Oderland

    Neuenhagen, 15366

  • KliFOs - Klinische Forschung Osnabrueck

    Osnabrück, 49074

  • Studienzentrum Dr. Sabine Lassmann

    Saalfeld, 07318

  • Klinische Forschung Schwerin GmbH

    Schwerin, 19055

  • Klinikum Stuttgart - Krankenhaus Bad Cannstatt (KBC) - Frauenklinik

    Stuttgart, 70374

  • Dres. med. Josef und Wilma Grosskopf

    Wallerfing, 94574

Other trials in Germany

Poland23 sites

  • Prywatny Gabinet Internistyczno - Alergologiczny

    Bialystok, 15010

  • Allergy Clinic Homeo Medicus

    Bialystok, 15687

  • Centrum Medyczne Czestochowa - PRATIA - PPDS

    Częstochowa, 42200

  • Centrum Medyczne Pratia Katowice

    Katowice, 40081

  • Specjalistyczna Praktyka Lekarska dr n. med. Joanna Orlicz-Widawska

    Katowice, 40338

  • ETG Kielce

    Kielce, 25355

  • Centrum Nowoczesnych Terapii Dobry Lekarz Sp. z o.o.

    Krakow, 31011

  • Krakowskie Centrum Medyczne

    Krakow, 31501

  • Malopolskie Centrum Alergologii

    Krakow, 31624

  • Uniwersytecki Szpital Kliniczny im. Barlickiego, Poradnia alergologii i chorob pluc

    Lodz, 90153

  • ETG Łódz

    Lodz, 90302

  • Clinical Best Solutions Sp. Z O.O. Spółka Komandytowa

    Lublin, 20078

  • Centrum Alergologii Teresa Hofman Sp. z o.o.

    Poznan, 60214

  • Specjalistyczna Przychodnia Lekarska ALERGO-MED Sp. z.o.o.

    Poznan, 61578

  • EMED Centrum Uslug Medycznych Ewa Śmiałek

    Rzeszów, 35205

  • ETG Skierniewice

    Skierniewice, 96100

  • ALERGO-MED Specjalistyczna Przychodnia Lekarska Sp. z.o.o

    Tarnów, 33100

  • Specjalistyczne Centrum Medyczne Centermed Sp. z o.o.

    Tarnów, 33100

  • IRMED Irena Wojciechowska

    Warsaw, 01157

  • WK Medical Service Sp. z o.o.

    Warsaw, 02-119

  • "ALL-MED" Specjalistyczna Opieka Medyczna, Medyczny Instytut Badawczy

    Wroclaw, 53201

  • Michał Bogacki - DOBROSTAN

    Wroclaw, 53301

  • Niepubliczny Zakład Opieki Zdrowotnej Przychodnia Lekarska Hipokrates Sp. z o.o.

    Zabrze, 41800

Other trials in Poland

Czechia9 sites

  • Fakultní nemocnice u sv. Anny v Brně

    Brno, 60200

  • MUDr. Jana Poloniová - alergologie a klinická imunologie

    České Budějovice, 37001

  • Alergopraktik, s.r.o.

    Jablonec nad Nisou, 46601

  • Alergologie a imunologie MUDr. Hofstetr

    Jihlava, 58601

  • Alergoimuno s.r.o.

    Ostrava-Hrabuvka, 70030

  • ACREDULA BENEDICTA s.r.o.

    Pardubice, 53002

  • Fakultní nemocnice Plzeň

    Pilsen, 30460

  • KASMED, s.r.o.

    Tábor, 39002

  • MŮJ ALERGOLOG s.r.o.

    Trutnov, 54101

Other trials in Czechia

Austria4 sites

  • Medizinische Universitaet Innsbruck - Universitatsklinik fuer Dermatologie, Venerologie und Allergologie

    Innsbruck, 6020

  • Bezirkskrankenhaus Kufstein

    Kufstein, 6330

  • Medizinische Universitat Wien (Medical University of Vienna)

    Vienna, 1090

  • Ambulatorium für Allergie und klinische Immunologie AAKI

    Vienna, 1100

Other trials in Austria

Hungary4 sites

  • Gróf Tisza István Kórház Rendelőintézet MEDIDOCUMENT Kereskedelmi és Szolgáltató Betéti Társaság

    Berettyóújfalu, 4100

  • Clinexpert Kft

    Budapest, 1033

  • HiTech Medical Kft.

    Budapest, 1064

  • Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar

    Pécs, 7621

Other trials in Hungary

About this study

Official title: A Randomised, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen Exposure

The PQGrass306 (G306) clinical trial is the pivotal Phase III efficacy clinical trial of PQ Grass.

The aim of the G306 pivotal clinical trial is to confirm the efficacy and safety of the optimal effective dose of PQ Grass 27600 SU. This will be determined through the measurements of the effect of PQ Grass on the symptoms of seasonal allergic rhinitis (SAR)/rhinoconjunctivitis and the use of relief medications to control these symptoms during the peak grass pollen season (GPS).

Read the detailed description

Multi-centre, randomised, parallel group, double-blind, placebo-controlled clinical trial to confirm the efficacy and safety of the optimal effective dose of PQ Grass (27600 SU).

Randomized study subjects, in a randomisation ratio of 1:1, will receive either treatment with 6 injections of active treatment (900, 2700, 6000, 6000, 6000 and 6000 SU sequentially) to achieve a cumulative nominal dose of 27600 SU, or 6 injections of placebo prior to the onset of the grass pollen season (GPS).

The aim of the study is to confirm the efficacy and safety of the optimal effective dose of the PQ Grass 27600 SU dose. Efficacy will be determined through the measurements of the effect of PQ Grass on the symptoms of seasonal allergic rhinitis (SAR)/rhinoconjunctivitis and the use of relief medications to control these symptoms during the peak GPS.

Being tested
PQ Grass, Placebo
Medical subject headings
Rhinitis, Allergic, Seasonal

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PQ GrassBiological

    Suspension for Injection

  • PlaceboBiological

    Solution for injection

Study groups in NCT05540717
Study groupRoleWhat they receive
PQ GrassExperimental6 subcutaneous injections of active treatment (900, 2700, 6000, 6000, 6000 and 6000 SU sequentially) to achieve a cumulative nominal dose of 27600 SU
Receives: Biological: PQ Grass
PlaceboPlacebo comparator6 subcutaneous injections of placebo
Receives: Biological: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Combined Symptom and Medication Score (CSMS) Averaged Over the Peak Grass Pollen Season (GPS)

    The daily CSMS is calculated as the sum of the daily Symptom Score (dSS) and the daily Medication Score (dMS).

    The dSS component of the CSMS is calculated as the sum of 6 individual symptom (2 conjunctival and 4 nasal) scores, each with a range of 0 to 3 points and divided by 6, and therefore has a total range between 0 and 3.

    The dMS is a score assigned according to the step of relief medication used in a day (from 0: no relief medication to 3: oral corticosteroids with step and step 2 medications).

    The daily CSMS has a range between 0 and 6. The average CSMS over the peak GPS will be calculated as sum of the daily CSMS within the peak GPS divided by the number of days of the peak GPS where the CSMS has been collected. Higher values in the scale represent worse outcomes.

    Measured: dSS and dMS are recorded daily between Visit 8 (wk 16-29) and Visit 11 (wk 28-41). Then CSMS is adjusted to the Peak GPS, which depends on the GPS start and end dates for each region

Secondary outcomes (22)

  1. Combined Symptom and Medication Score (CSMS) Averaged Over the Entire (or Truncated) Grass Pollen Season (GPS)

    6 individual symptoms assessed in a 4 point severity scale (0-No symptoms to 3-Severe symptoms) and combined with relief medication use assessed using a 4 point severity scale (0=No relief medication, 1=anti-histamine use, 2=nasal corticosteroid use, and 3=oral corticosteroid use)

    Measured: dSS and dMS are recorded daily between Visit 8 (wk 16-29) and Visit 11 (wk 28-41). Then CSMS is adjusted to the entire GPS, which depends on the GPS start and end dates for each region

  2. Daily Medication Score (dMS) Component of the CSMS Averaged Over the Peak GPS and Entire (or Truncated) GPS

    The dMS is calculated from the daily use of relief medication. Scores are assigned following the scheme:

    Score 0: no relief medication used Score 1: Oral antihistamine/Ocular antihistamine Score 2: Intranasal corticosteroid with Step 1 medication(s) Score 3: Oral corticosteroids with Step 1 and Step 2 medications The maximum dMS corresponds to a score of 3, which would indicate worse symptoms in the patient.

    Measured: dMS of the CSMS was recorded daily between Visit 8 (wk 16-29) and Visit 11 (wk 28-41). Then dMS is adjusted to the peak or entire GPS

  3. Daily Symptom Score (dSS) Component of the CSMS Averaged Over the Peak GPS and Entire (or Truncated) GPS

    dSS score is based on the sum of the score of 6 symptoms using a 4-point severity scale as follows: 0 = No symptoms

    1. = Mild symptoms
    2. = Moderate symptoms
    3. = Severe symptoms

    The dSS is calculated as the sum of the scores for the 6 individual symptoms, divided by 6. Higher values in the scale indicate worse symptoms.

    Measured: dSS of the CSMS was recorded daily between Visit 8 (wk 16-29) and Visit 11 (wk 28-41). Then dMS is adjusted to the peak or entire GPS

  4. Average Rhinoconjunctivitis Quality of Life Questionnaire With Standardized Activities (RQLQ(S)) Measured Within the Peak GPS

    RQLQ(S) is a health-related quality of life instrument that measures the functional impairments that are most troublesome to adults.

    It is measured in a 7-point scale (0 = not impaired at all - 6 = severely impaired) with higher scores reflecting a lower quality of life.

    Measured: RQLQ(s) is performed at Visit 2 (wk 2-8), Visit 9 (wk 18-31) and Visit 10 (wk 23-36).

  5. Change in Serum Grass-specific IgG4 (Immunoglobulin G4) From Baseline to Visit 7.

    Serum grass-specific IgG4 was measured at baseline and at visit 7

    Measured: Serum grass-specific IgG4 was measured at Visit 1 (baseline) and Visit 7 (wk 12-25)

  6. Number of Well Days During the Peak GPS

    A "well day" was defined based on CSMS as a day with:

    • No use of relief medication on the particular day, i.e., CSMS-dMS = 0;
    • And a total dSS, i.e., CSMS-dSS ≤ 2 out of 18 of the raw scores.

    Measured: dMS and dSS was recorded daily between Visit 8 (wk 16-29) and Visit 11 (wk 28-41). Then number of well days was calculated during peak GPS.

  7. Frequency, Severity and Relationship of AEs (Adverse Event) to Treatment

    Number of subjects with at least one event of the specified AE type

    Measured: From visit 1 (baseline) to last follow-up call (week 46)

  8. Frequency of AEs Leading to Premature Discontinuation From Treatment or Clinical Trial

    Number of subjects with at least one event of the specified AE type

    Measured: From visit 1 (baseline) to last follow-up call (week 46)

  9. Frequency of AESI (Adverse Events of Special Interest)

    Number of subjects with at least one event of the specified AE type

    Measured: From visit 1 (baseline) to last follow-up call (week 46)

  10. Changes in Serum Chemistry Values (Sodium, Potassium and Chloride) Between Baseline and Visit 11

    Measured: From Visit 1 (baseline) to visit 11 (week 28-41)

  11. Changes in Serum Chemistry Values (Glucose, Uric Acid, Urea, Phosphorus and Cholesterol) Between Baseline and Visit 11

    Measured: From Visit 1 (baseline) to visit 11 (week 28-41)

  12. Changes in Serum Chemistry Values ( Calcium, Creatinine and Total Bilirubin) Between Baseline and Visit 11

    Measured: From Visit 1 (baseline) to visit 11 (week 28-41)

  13. Changes in Serum Chemistry Values (Total Protein and Albumin) Between Baseline and Visit 11

    Measured: From Visit 1 (baseline) to visit 11 (week 28-41)

  14. Changes in Serum Chemistry Values (Alkaline Phosphatase, Lactate Dehydrogenase, Aspartate Aminotransferase, Alanine Aminotransferase and Gamma-glutamyl Transferase) Between Baseline and Visit 11

    Measured: From Visit 1 (baseline) to visit 11 (week 28-41)

  15. Changes in Serum Chemistry Values (C-reactive Protein) Between Baseline and Visit 11

    Measured: From Visit 1 (baseline) to visit 11 (week 28-41)

  16. Changes in Haematology Values (Red Blood Cells) Between Baseline and Visit 11

    The outcome includes total red blood cells number at visit 11 and change from baseline expressed as cells x 10^12/L

    Measured: From Visit 1 (baseline) to visit 11 (week 28-41)

  17. Changes in Hematology Values (White Blood Cells and Platelets) Between Baseline and Visit 11

    Outcomes include the change from baseline in the number of white blood cells and platelets expressed as cells x 10^9/L

    Measured: From Visit 1 (baseline) to visit 11 (week 28-41)

  18. Change in Hematology Values (Hemoglobin) Between Baseline and Visit 11

    Measured: From Visit 1 (baseline) to visit 11 (week 28-41)

  19. Changes in Clinical Laboratory Values (Urinalysis: pH) Between Baseline and Visit 11

    Urinalysis was performed using a urine dip-stick - Results were assessed by the investigators as clinical significant or not.

    The pH is measured in a scale from 0 to 14 (being 0 the most acid and 14 the most basic values)

    Measured: From Visit 1 (baseline) to visit 11 (week 28-41).

  20. Clinical Laboratory Values (Urinalysis: Protein, Glucose, Bilirubin, Blood and Leukocytes) at Baseline and Visit 11

    Urinalysis was determined using a urine dip-stick - Results were scored as zero, traces, +1, +2, +3, +4 (being zero no detection of the parameter, and 4 the maximum value) Note: Microscopic examination was conducted if protein, leukocytes and/or blood are detected. If needed, microscopic examination included white blood cells, red blood cells, casts, and bacteria.

    Measured: From Visit 1 (baseline) to visit 11 (week 28-41)

  21. Clinical Laboratory Values (Urinalysis: Ketones, Nitrite, Urobilinogen ) at Baseline and Visit 11

    Urinalysis was performed using a urine dip-stick - Results were represented as negative or positive Note: Microscopic examination was conducted if nitrite was detected. If needed, microscopic examination included white blood cells, red blood cells, casts, and bacteria.

    Measured: From Visit 1 (baseline) to visit 11 (week 28-41)

  22. Changes in Vital Signs (Systolic and Diastolic Blood Pressure) From Baseline to All Treatment Visits

    Blood pressure was measured (in millimeters of mercury) at all treatment visits: Visit (V)1, V2 (2-8 weeks), V3 (3-9 weeks), V4 (4-10 weeks), V5 (7-15 weeks), V6 (10-20 weeks), V7 (week 13-25), V8 (16.29 weeks), V9 (18-31 weeks), V10 (23-36 weeks), V11 (28-41 weeks). At Visits 2 to 7, vital sign measurements were performed before and 30 to 60 minutes following investigational drug/placebo administration.

    Measured: From Visit 1 (baseline) to visit 11 (week 28-41)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Sep 2022
  2. Study start11 Oct 2022
  3. Primary completion1 Nov 2023
  4. Study completion1 Nov 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
555 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05540717
Sponsor's protocol ID
PQGrass306
Other IDs
2019-001517-16, 2019
Status last verified
Feb 2025
First submitted
1 Sep 2022
Last updated
2 Apr 2025
FDA-regulated drug
Yes
FDA-regulated device
No

Publications

  • Layhadi JA, Starchenka S, De Kam PJ, Palmer E, Wu LYD, Keane ST, Fulton WT, Hikmawati P, Meng X, Filipaviciute P, Cutrina Pons A, Oluwayi K, Lis K, Armfield O, Skinner MA, Heath MD, Hewings SJ, Kramer MF, Shamji MH. Modulation of Cellular, Molecular, and Humoral Responses by PQ Grass 27,600 SU for the Treatment of Seasonal Allergic Rhinitis: A Randomised Double Blind Placebo Control Exploratory Field Study. Allergy. 2026 Jan;81(1):232-247. doi: 10.1111/all.16640. Epub 2025 Jul 8.

    PubMed 40626378

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing PQ Grass in people with Seasonal Allergic Rhinitis and Rhinoconjunctivitis, run by Allergy Therapeutics at 102 sites in 6 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 55 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 102 sites in United States, Germany, Poland, Czechia, Austria and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 2 Apr 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Combined Symptom and Medication Score (CSMS) Averaged Over the Peak Grass Pollen Season (GPS) (time frame: dSS and dMS are recorded daily between Visit 8 (wk 16-29) and Visit 11 (wk 28-41). Then CSMS is adjusted to the Peak GPS, which depends on the GPS start and end dates for each region). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05540717, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Apr 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in